Exhaled breath biopsy: a new cancer detection paradigm

References

• 1. Arasaradnam RP, McFarlane MJ, Ryan-Fisher C et al. Detection of colorectal cancer (CRC) by urinary volatile organic compound analysis. PLoS ONE 9(9), e108750 (2014).
  MedlineGoogle Scholar
• 2. Owlstone Medical. LuCID: a multi-centre prospective trial for lung cancer screening (2019). www.owlstonemedical.com/clinical-pipeline/lucid/
  Google Scholar
• 3. Owlstone Medical. InTERCEPT: the early detection of colorectal cancer aiming to save thousands of lives every year (2019). www.owlstonemedical.com/clinical-pipeline/intercept/
  Google Scholar
• 4. Owlstone Medical. STRATA: selecting the right treatment for severe asthma patients by replacing the trial and error approach (2019). www.owlstonemedical.com/clinical-pipeline/strata/
  Google Scholar
• 5. Clinical Trials database: NCT03756597. https://clinicaltrials.gov/ct2/show/NCT03756597
  Google Scholar
• 6. Owlstone Medical Ltd. Owlstone Medical's Breath Biopsy^® Platform (2019). www.owlstonemedical.com/science-technology/breath-biopsy/
  Google Scholar
• 7. Environmental Protection Agency. Definition of volatile organic compound. (1978). www.epa.gov/ttn/naaqs/aqmguide/collection/Doc_0016_VOC330701781.pdf
  Google Scholar
• 8. De Lacy Costello B, Amann A, Al-Kateb H et al. A review of the volatiles from the healthy human body. J. Breath. Res. 8(1), 014001 (2014).
  MedlineGoogle Scholar
• 9. Gaude E, Frezza C. Tissue-specific and convergent metabolic transformation of cancer correlates with metastatic potential and patient survival. Nat. Commun. 7, 13041 (2016).
  Medline CASGoogle Scholar
• 10. Warburg O. On the origin of cancer cells. Science 123(3191), 309–314 (1956).
  Medline CASGoogle Scholar
• 11. Tennant DA, Duran RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer 10(4), 267–277 (2010).
  Medline CASGoogle Scholar
• 12. Queralto N, Berliner AN, Goldsmith B, Martino R, Rhodes P, Lim SH. Detecting cancer by breath volatile organic compound analysis: a review of array-based sensors. J. Breath. Res. 8(2), 027112 (2014).
  Medline CASGoogle Scholar
• 13. Van Der Schee M, Pinheiro H, Gaude E. Breath biopsy for early detection and precision medicine in cancer. Ecancermedicalscience 12, ed84 (2018).
  MedlineGoogle Scholar
• 14. Harding P, Field PH. Breathalyzer accuracy in actual law enforcement practice: a comparison of blood- and breath-alcohol results in Wisconsin drivers. J. Forensic Sci. 32(5), 1235–1240 (1987).
  Medline CASGoogle Scholar
• 15. Atreja A, Fu AZ, Sanaka MR, Vargo JJ. Non-invasive testing for Helicobacter pylori in patients hospitalized with peptic ulcer hemorrhage: a cost–effectiveness analysis. Dig. Dis. Sci. 55(5), 1356–1363 (2010).
  MedlineGoogle Scholar
• 16. Petrone P, Sarkisyan G, Fernandez M et al. Small intestinal bacterial overgrowth in patients with lower gastrointestinal symptoms and a history of previous abdominal surgery. Arch. Surg. 146(4), 444–447 (2011).
  MedlineGoogle Scholar
• 17. Robroeks CM, Van Berkel JJ, Jobsis Q et al. Exhaled volatile organic compounds predict exacerbations of childhood asthma in a 1-year prospective study. Eur. Respir. J. 42(1), 98–106 (2013).
  Medline CASGoogle Scholar
• 18. Hübschmann H-J. Chapter 3: The historical development of the GC-MS technique. In: Handbook of GC-MS: Fundamentals and Applications (3rd Edition). Wiley-VCH, Weinheim, Germany. (2015).
  Google Scholar
• 19. Pauling L, Robinson AB, Teranishi R, Cary P. Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. Proc. Natl Acad. Sci. USA 68(10), 2374–2376 (1971).
  Medline CASGoogle Scholar
• 20. WHO. Guide to cancer early diagnosis. (2017). https://apps.who.int/iris/bitstream/handle/10665/254500/9789241511940-eng.pdf;jsessionid=4BEC54447715A45A8F035BCC110C119C?sequence=1
  Google Scholar
• 21. Cancer Action Network American Cancer Society. The costs of cancer: addressing patient costs. (2017). www.fightcancer.org/sites/default/files/Costs%20of%20Cancer%20-%20Final%20Web.pdf
  Google Scholar
• 22. UK Government Department of of Health and Social Care. 2010 to 2015 government policy: cancer research and treatment. (2015). www.gov.uk/government/publications/2010-to-2015-government-policy-cancer-research-and-treatment/2010-to-2015-government-policy-cancer-research-and-treatment
  Google Scholar
• 23. UK Government Department of of Health and Social Care. Improving outcomes: a strategy for cancer. (2011). www.gov.uk/government/publications/the-national-cancer-strategy
  Google Scholar
• 24. Sultana J, Cutroneo P, Trifiro G. Clinical and economic burden of adverse drug reactions. J. Pharmacol. Pharmacother. 4(Suppl. 1), S73–S77 (2013).
  MedlineGoogle Scholar
• 25. Policy Research Unit in Economic Evaluation of Health & Care Interventions (EEPRU). Prevalence and economic burden of medication errors in the NHS in England (2018) www.eepru.org.uk/wp-content/uploads/2018/02/eepru-report-medication-error-feb-2018.pdf 29- www.consort-statement.org/
  Google Scholar
• 26. Markar SR, Chin ST, Romano A et al. Breath volatile organic compound profiling of colorectal cancer using selected ion flow-tube mass spectrometry. Ann. Surg. 269(5), 903–910 (2019).
  MedlineGoogle Scholar
• 27. American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am. J. Respir. Crit. Care Med. 171(8), 912–930 (2005).
  MedlineGoogle Scholar
• 28. Cohen JF, Korevaar DA, Altman DG et al. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open 6(11), e012799 (2016).
  MedlineGoogle Scholar
• 29. Consort Transparent Reporting of Trials. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials (2010).
  Google Scholar